Science & Enterprise subscription

Follow us on Twitter

  • Don't let the perfect be the enemy of the good ...
    about 18 hours ago
  • Among the tech giants, Apple is the most aggressive in acquiring start-ups developing A.I. applications over the pa…
    about 1 day ago
  • New post on Science and Enterprise: Infographic – Apple Leads in A.I. Acquistions #Science #Business
    about 1 day ago
  • HBCUs still hand out more bachelor's degrees in STEM fields to Blacks than traditionally white institutions, but no…
    about 2 days ago
  • Special to Science and Enterprise ... HBCUs Still Putting Blacks in STEM by @crparks3…
    about 2 days ago

Please share Science & Enterprise

Biotech Secures $13M in Series B Funding for Clinical Trial

Blood bag (NIH)

(National Institutes of Health)

HemaQuest Pharmaceuticals Inc., a biotechnology company in San Diego, closed a $13 million extension of its series B financing, the second round of funding after initial start-up. The extension is funded by existing investors Aberdare Ventures, De Novo Ventures, Forward Ventures, Latterell Venture Partners, and Lilly Ventures.

HemaQuest develops small molecule therapies to treat disorders in hemoglobin, the protein in red blood cells that carries oxygen. The financing is expected to fund a phase 2b clinical test of the company’s lead candidate HQK-1001 in patients with sickle cell disease.  HQK-1001 is an orally administered drug derived from short-chain fatty acids designed to induce fetal globin and stimulate red blood cell production. These properties address the mechanisms underlying the blood disorders sickle cell anemia and beta thalassemia.

Sickle cell anemia is a disease passed down through families in which red blood cells form an abnormal crescent shape, rather than the normal disc shape. The sickle-shaped cells deliver less oxygen to the body’s tissues, and can get stuck more easily in small blood vessels, interrupting healthy blood flow. Beta thalassemia is also an inherited a blood disorder, where the body makes an abnormal form of hemoglobin and results in excessive destruction of red blood cells, which leads to anemia.

The technology behind HQK-1001 was first developed at Boston University by a research team that included HemaQuest co-founder Susan Perrine, a professor of medicine, pediatrics, pharmacology, and experimental therapeutics at BU. The drug has completed animal toxicology studies and phase 1 clinical trials that show it is safe and well-tolerated.

This financing extension is expected to allow the company to complete the phase 2b trial of HQK-1001 and fund operations through early 2014.

Read more: Simple Blood Test Checks Sickle Cell Anemia Symptoms Risk

*     *     *

Please share Science & Enterprise ...

Comments are closed.